Targets › TRAC
4 programs from 4 companies in 4 trials: 2 Phase 2, 2 Phase 1; Oncology; next expected readout Dec 2026.
Constant region of T cell receptor (TR) alpha chain. Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. (UniProt, P01848)
Open in Phaseline: the race on TRAC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Birmingham | Thymoglobulin Polyclonal antithymocyte globulin (ATG) for T cell depletion; binds to T cell surface anti | TRAC | Phase 2 | Acute Myeloid Leukemia | Aug 2027 |
| Peking University People's Hospital | Reduced ATG plus mini PTCy Combination of anti-thymocyte globulin (ATG) and post-transplantation cyclophosphamide (PT | TRAC, TRBC1, TRBC2 | Phase 2 | Myelodysplastic Syndrome | – |
| Chiome Bioscience | CBA-1535 T cell engager (bispecific antibody engaging 5T4 and CD3) | TRAC, 5T4 | Phase 1 | Solid Tumors | Dec 2026 |
| Chinese PLA General Hospital | Allogeneic CD19-STAR T cell Allogeneic T cells with TRAC locus-inserted CD19-targeting synthetic TCR, with endogenous | CD19, TRAC | Phase 1 | Non-hodgkin Lymphoma,B Cell | Mar 2027 |
Myelodysplastic Syndrome (1) Non-hodgkin Lymphoma,B Cell (1) Solid Tumors (1) Acute Myeloid Leukemia (1)
small molecule (2), mixed (2)
Peking University People's Hospital (1) Chinese PLA General Hospital (1) Chiome Bioscience (1) University of Birmingham (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.